Efficacy of botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: experience of the Botulinum Toxin Outpatients Department

Aleksandra Tomić; Balša Vujović; Nataša Dragašević Mišković; Igor Petrović; Tatjana Pekmezović; Vladimir S Kostić

doi:10.2298/5224

Aleksandra Tomić Klinika za neurologiju, Klinički centar Srbije, Beograd Clinic for Neurology, Clinical Center of Serbia, Belgrade
Balša Vujović Clinic for Neurology, Clinical Center of Montenegro, Podgorica, Montenegro
Nataša Dragašević Mišković Clinic for Neurology, Clinical Center of Serbia, Belgrade, Serbia
Igor Petrović Clinic for Neurology, Clinical Center of Serbia, Belgrade, Serbia
Tatjana Pekmezović Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Vladimir S Kostić Clinic for Neurology, Clinical Center of Serbia, Belgrade, Serbia

DOI: https://doi.org/10.2298/5224

Abstract

Background/Aim. Botulinum toxin (BTX) irreversibly inhibits presynaptic acetylcholine release with subsequent relaxation of abnormally contracting muscles. It is an effective and well tolerated treatment with long-term benefit in a variety of movement disorders and other neurological and non-neurological disturbances. The aim of our study was to present our experience with BTX type A in treatment of different forms of focal dystonias. Мethods. А hundred of patients with different focal dystonias (spastic torticollis, blepharospasm and graphospasm) from the Botulinum Toxin Outpatients Department, Clinic for Neurology, Clinical Center of Serbia, were included in the study. All the patients were examined and rated at baseline visit prior to BTX application and on the following visit, after 3–4 months, using self-assessment improvement questionnaire and standardized rating scales. Results. The improvement of ≥ 50% was presented in 68.2% of all (199) the analyzed applications. Independent predictors of good response to the therapy (improvement ≥ 50%) were male sex (p = 0.011), the presence of sensory trick (p = 0.013) and the total number of BTX applications (p = 0.002). The patients with spastic torticollis and blepharospasm showed a statistically significantly better BTX effect (improvement 57.3 ± 27.5% and 54.1 ± 28.3%), respectively than the graphospasm group (26.7 ± 25.6%). Most of the patients did not have therapy complications (81.4% and 72% in two applications). Side effects in the remaining patients (muscle weakness, dysphagia, ptosis, double vision, neck weakness and lacrimal dysfunction) lasted for 28.3 ± 18.6 days after the first treatment and 32.5 ± 36.2 days after the second one. Conclusion. BTX is safe and highly effective in long-term treatment of patients with different forms of focal dystonia, with only mild and well- tolerated side-effects.

Key words:

dystonia; botulinum toxins; serbia; questionnaires; quality of life

References

Ramirez-Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins 2013; 5(2): 249−66.

Dressler D, Adib SF. Botulinum Toxin: Mechanisms of Action. Eur Neurol 2005; 53(1): 3−9.

Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 2005; 25(1): CD004315.

Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord 2004; 19 (Suppl 8): S109−15.

Costa J, Espírito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev 2005; 25(1) CD004900.

Schuele S, Jabusch H, Lederman RJ, Altenmüller E. Botulinum toxin injections in the treatment of musician's dystonia. Neurology 2005; 64(2): 341−3.

Karp BI. The role of botulinum toxin type A in the management of occupational dystonia and writer's cramp. In: Brin MF, Jankovic J, Hallet M, editors. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams and Wilkins; 2000. p. 251−8

Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, de Haan RJ, Speelman JD. Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatr 2007; 78(3): 264−70.

Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002; 17(6): 1288−93.

Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 2011; 18(1): 5−18.

Consky ES, Lang AE. Clinical assessments in patients with cervical dystonia. In: Jankovic J, Hallet M, editors. Therapy with botulinum toxin. New York, NY: Marcel Dekker; 1994. p. 211−37.

Goertelmeyer R, Brinkmann S, Comes G, Delcker A. The Blepharospasm Disability Index (BSDI) for the assessment of functional health in focal dystonia. Clin Neurophysiol 2002; 113(1): S77−8.

Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987; 37(4): 616−23.

Wissel J, Kabus C, Wenzel R, Klepsch S, Schwarz U, Nebe A, et al. Botulinum toxin in writer's cramp: objective response evaluation in 31 patients. J Neurol Neurosurg Psychiatr 1996; 61(2): 172−5.

Kostić V, Covicković-Sternić N, Filipović S. Local treatment of spasmodic torticollis with botulinum toxin. Neurologija 1990;39(1):29-33.

Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W. Patients' perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord 2000; 15(1): 150−3.

Skogseid IM, Kerty E. The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 2005; 12(3): 163−70.

Cillino S, Raimondi G, Guépratte N, Damiani S, Cillino M, di Pace F, et al. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation index. Eye (Lond) 2010; 24(4): 600−7.

Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo FS, Albanese A. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res 2009; 15(3): 224−31.

Lungu C, Karp BI, Alter K, Zolbrod R, Hallett M. Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more. Mov Disord 2011; 26(4): 750−3.

Byrnes ML, Thickbroom GW, Wilson SA, Sacco P, Shipman JM, Stell R, et al. The corticomotor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection. Brain 1998; 121(Pt 5): 977−88.

Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006; 13(Suppl 4): 35−40.

Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005; 20(5): 592−7.